Set forth below is a discussion of the financial condition and results of operations for the Group for the six month period ending June 30, 2003. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and Notes for the six month period ended June 30, 2003 included herein.
Set forth below is a discussion of turnover for each of our principal businesses.
Electronic Materials’ turnover increased from £28.9 million for the six months ended June 30, 2002 to £29.2 million for the six months ended June 30, 2003, an increase of 1.0%. Electronic Materials’ sales have increased mainly due to improved customer demand as order patterns for ink jet printing consumables returned to a more normal pattern following the de-stocking of these materials in 2002, offset by the impact of adverse exchange rates. Electronic Materials’ turnover decreased from £18.4 million for the three months ended June 30, 2002 to £15.8 million for the three months ended June 30, 2003, a decrease of 14.1%, mainly due to the impact of adverse exchange rates, and lower customer demand for ink jet printing consumables.
Fine Chemicals’ turnover decreased from £79.5 million for the six months ended June 30, 2002 to £67.3 million for the six months ended June 30, 2003, a decrease of 15.3%. Fine Chemicals’ turnover decreased from £45.3 million for the three months ended June 30, 2002 to £27.6 million for the three months ended June 30, 2003, a decrease of 39.1%. Fine Chemicals turnover has decreased due to a decline in demand for pharmaceutical custom large-scale manufacturing, and due to lower manufacture of DNA medicines caused by preparations for GMP validation and manufacture and preparation for capacity increases.
Specialty Products’ turnover decreased from £86.8 million for the six months ended June 30, 2002 to £72.1 million for the six months ended June 30, 2003, a decrease of 16.9%. Specialty Products’ turnover decreased from £44.6 million for the three months ended June 30, 2002 to £36.6 million for the three months ended June 30, 2003, a decrease of 17.9%. Specialty Products’ turnover decrease is mainly due to the exit from the Pigments business at the end of 2002 and the adverse currency effects caused by the weakening of the US Dollar.
NeoResins’ turnover increased from £86.6 million for the six months ended June 30, 2002, to £90.3 million for the six months ended June 30, 2003, an increase of 4.3%. NeoResins’ turnover increased from £44.5 million for the three months ended June 30, 2002, to £46.7 million for the three months ended June 30, 2003, an increase of 4.9%. NeoResins’ increase in turnover reflects increased customer demand for the business’ specialized water-borne resin technologies, and favourable exchange effects.
Back to Contents
Avecia Group plc
Management’s Discussion and Analysis of Financial Conditions and Results of Operations — (continued)
Operating profit / (loss)
Total operating results decreased from £10.3 million profit for the six months ended June 30, 2002 to £39.9 million loss for the six months ended June 30, 2003. Total operating results decreased from £13.1 million profit for the three months ended June 30, 2002 to £44.3 million loss for the three months ended June 30, 2003.
Electronic Materials’ operating results increased from £2.0 million loss in the six months ended June 30, 2002, to £0.5 million profit for the six months ended June 30, 2003. Electronic Materials’ operating results decreased from £1.3 million profit in the three months ended June 30, 2002, to £1.0 million profit for the three months ended June 30, 2003. The change in profits was mainly due to the changes in sales noted above.
Fine Chemicals’ operating results decreased from a loss of £1.7 million for the six months ended June 30, 2002, to a loss of £40.0 million for the six months ended June 30, 2003. Fine Chemicals’ operating results decreased from a profit of £3.8 million for the three months ended June 30, 2002, to a loss of £37.1 million for the three months ended June 30, 2003. Fine Chemicals’ operating results decreased against 2002 mainly due to an impairment charge taken against fixed asset values of £27 million, together with the sales decreases noted above, and higher costs as additional resources were added to support increased capacity in the Biotechnology business.
Specialty Products’ operating profit decreased from a profit of £16.9 million for the six months ended June 30, 2002 to a profit of £15.2 million for the six months ended June 30, 2003. Specialty Products’ operating profit decreased from £9.2 million profit for the three months ended June 30, 2002 to £7.5 million profit for the three months ended June 30, 2003. The decrease in operating profits was mainly due to the changes in sales noted above.
NeoResins’ operating profit decreased from a profit of £16.3 million for the six months ended June 30, 2002 to £14.4 million for the six months ended June 30, 2003, NeoResins’ operating profit decreased from £8.9 million for the three months ended June 30, 2002 to £7.0 million for the three months ended June 30, 2003 with the increased sales noted above offset by increases in raw material and shipping costs, which outpaced NeoResins’ ability to secure price increases.
Central costs, including goodwill amortisation, increased from £19.8 million for the six months ended June 30, 2002 to £30.3 million for the six months ended June 30, 2003, due to additional amortisation of goodwill of £12.5 million.
Share of operating profit from joint ventures
Our pro-rata share of the earnings from both of our Image Polymers joint ventures decreased from £1.5 million for the six months ended June 30, 2002, to £1.0 million for the six months ended June 30, 2003. Our pro-rata share of the earnings from both of our Image Polymers joint ventures decreased from £0.6 million for the three months ended June 30, 2002, to £0.5 million for the three months ended June 30, 2003.
Profit on ordinary activities before interest and tax
The net profit decreased from £22.3 million profit for the six months ended June 30, 2002 to £38.8 million loss for the six months ended June 30, 2003. The net profit decreased from £12.3 million for the three months ended June 30, 2002 to £43.8 million loss for the three months ended June 30, 2003.
Net interest
Net interest expense for the six months to June 30, 2003 was £19.2 million, compared to a net expense of £17.7 million for the six months to June 30, 2002. Net interest expense for the three months to June 30, 2003 was £3.5 million receivable, compared to a net receivable of £5.2 million for the three months to June 30, 2002. After allowing for the effects of unrealized exchange differences and reduced fee amortisation, the net decrease in the interest cost is due to lower interest rates and the effect of a weaker US Dollar on interest payments made in US Dollars.
Taxation
The charge for taxation for the six months to June 30, 2003 was £1.3 million against a charge of £3.2 million for taxation in the six months to June 30, 2002. The charge for taxation for the three months to June 30, 2003 was £0.9 million against a charge of £1.2 million for the three months to June 30, 2002.
Liquidity and capital resources
Cash generated from operations totalled £31.8 million inflow for the six months to June 30, 2003 compared to £32.6 million inflow for the six months to June 30, 2002. Operating income plus depreciation and amortization was £33.1 million in the six months to June 30, 2003 compared to £46.3 million in the six months to June 30, 2002. Working capital outflows in the six months to June 30, 2003 were £3.9 million compared to outflows of £16.7 million in the six months to June 30, 2002.
The Group’s net cash requirement for servicing debt in the six months of operation ended June 30, 2003 was £24.2 million comprising interest income of £0.5 million and interest paid of £24.7 million. The Group’s net cash requirement for servicing debt in the three months of operation ended June 30, 2003 was £5.3 million of interest paid.
Cash capital expenditure in the six months to June 30, 2003 was £24.9 million compared with a total of £20.3 million in the six months to June, 2002 , with the increase reflecting the construction of the new Advanced Biologics Centre in the UK.
In the six months to June 30, 2003 the cash outflow for taxation was nil. In the six months to June 30, 2002 the cash outflow for taxation was £1.5 million. In the three months to June 30, 2003 the cash inflow for taxation was £0.3 million. In the three months to June 30, 2002 the cash outflow for taxation was £0.9 million.
In the six months to June 30, 2003 the Group made payments of £1.9 million in respect of the acquisition of subsidiaries. This represents the deferred amounts due as part of the purchase of Covion. The deferred proceeds of the Stahl disposal were received in the six months to June 30, 2003.
In total, the above factors contributed to a net decrease in cash in the six months to June 30, 2003 of £13.9 million. For the six months to June 30, 2002 the net decrease in cash was £4.9 million.
At June 30, 2003 the group had outstanding external borrowings of £559.3 million, gross of capitalised issue costs, comprising £324.1 million of 11% Senior Notes due 2009, £135.0 million of Senior Secured Credit Facility repayable in semi-annual instalments between 2003 and 2006 (Term Loan A), £51.8 million of Senior Secured Credit Facility repayable in 2007 (Term Loan B), £48.4 million of Senior Secured Credit Facility repayable in 2008 (Term Loan C). Of the £100 million Senior Secured Revolving Credit, available until 2006, £2.0 million has been utilized as at June 30, 2003 to provide guarantee facilities, and £16.5 million has been utilized as at June 30, 2003 to provide overdraft facilities. None of the overdraft facilities had been utilised as at June 30, 2003.
Avecia has signed a definitive agreement with Cytec Industries Inc., to sell the Metal Extraction Products (MEP) and Intermediates & Stabilizers (I&S) businesses for approximately US$97 million in cash. Under the agreement, Cytec will acquire substantially all of the assets and liabilities of the businesses including the majority of assets at Avecia’s Mount Pleasant site, Tennessee. The MEP business forms part of the Specialty Products portfolio and the I&S business forms part of the Fine Chemicals segment. Net proceeds from the sale of these businesses will be used primarily to repay a portion of the Senior Secured Credit Facility. The disposal concludes on 31 July 2003, and the disposal proceeds and consequential prepayment of a portion of the Senior Secured Credit Facility will form part of Avecia’s financial statements for the nine months to September 30, 2003.
Back to Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Avecia Group plc |
| | |
Date: August 4, 2003 | By: | /s/: Derrick Nicholson |
| |
|
| Name: | Derrick Nicholson |
| Title: | Finance Director |